Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.1 Part 2

Dr. Joshua Reuss returns to the podcast to discuss the update to the living guideline on stage IV NSCLC with driver alterations. The conversation focuses on new cancer treatment strategies for patients with advanced NSCLC and EGFR mutations, including classical EGFR alterations (exon 19 deletions, exon 21 L858R substitution) and rarer alterations (exon 20 insertion mutations). Dr. Reuss discusses results from clinical trials, including MARIPOSA and CHRYSALIS-2 and how these impacted first-line and subsequent line treatment recommendations. He looks to the future on what new evidence and potential updates are in the pipeline for this living guideline. Read the full living guideline "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations, ASCO Living Guideline Version 2026.3.1"  [**LINK TO FULL TRANSCRIPT**](ascopubs.org/do/therapy-stage-iv-nsclc-driver-alterations-asco-living-guideline-update-2026-3-1-part-2)